ESR1 and breast cancer: Endocrine therapy has been the standard therapy for HR+ BC in the early and advanced stages with several agents, such as selective estrogen receptor modulators (SERMS), aromatase inhibitors (AIs) and selective estrogen receptor degraders (SERDs) [12].